About Us

Who We AreTransforming Cancer Care Through Precision and Innovation

At Theranib Inc., we are dedicated to revolutionizing cancer treatment by addressing the most pressing challenges in oncology: chemotherapy resistance and metastasis. Through our groundbreaking research and development of ALDH1A3-targeted therapies, we aim to deliver life-changing solutions for patients worldwide.

Founded by leading scientists from Dalhousie University in Nova Scotia, Canada, and the University of Pisa, Italy, Theranib combines world-class expertise in molecular cancer biology and medicinal chemistry. Our proprietary compound, CLM296, represents a first-in-class therapeutic innovation designed to enhance the effectiveness of cancer treatments and improve patient outcomes.

Supported by key funding sources, including the Canadian Institutes of Health Research and Invest Nova Scotia, we are advancing our mission to set a new standard in precision medicine. With a strong commitment to innovation and collaboration, Theranib is paving the way for the future of cancer care.

Theranib
Our Mission & VisionOur Commitment to a Better Future

Mission:
To develop innovative, ALDH1A3-targeted therapies that address the critical challenges of chemotherapy resistance and metastasis, transforming cancer care globally.

Vision:
To lead the next generation of oncology treatments through precision medicine, delivering hope and better outcomes for patients worldwide.

Our JourneyOur Commitment to a Better Future

Theranib Inc. was founded by a team of pioneering researchers at Dalhousie University and the University of Pisa, united by a mission to combat cancer at its molecular roots. Our discovery of ALDH1A3 as a key therapeutic target has paved the way for the development of CLM296, a first-in-class inhibitor designed to tackle cancer’s toughest challenges.

Supported by funding from leading Canadian and Nova Scotian institutions, we have grown from an academic collaboration into a global biotech innovator.

What We DoInnovating Cancer Care

Theranib focuses on addressing two of the most pressing challenges in oncology:

  • Chemotherapy Resistance: Developing therapies that enhance treatment efficacy by targeting ALDH1A3.
  • Metastasis Prevention: Innovating solutions to reduce the spread of secondary tumors.

Through our proprietary compound CLM296 and biomarker-driven diagnostics, we are setting a new standard for precision medicine, ensuring tailored treatments for patients most likely to benefit.

Our TeamMeet the Visionaries Driving Cancer Innovation

Growing team of experts, including leading scientists, researchers, and innovators driving advancements in cancer care.

Paola Marcato 1 cropped (1) (1)
Dr. Paola MarcatoCo-Founder and Co-President of Theranib
thumbnail_IMG_4715 (1)
Dr. Concettina La MottaCo-Founder and Co-President of Theranib

Achievements and RecognitionMilestones of Excellence

2023
Invest Nova Scotia
Phase I funding: “Investigating a novel rationally-designed potent ALDH1A3 inhibitor for the treatment of cancer”
2024
Springboard, Atlantic IP Advantage Funding
Theranib Inc. Startup
2024
Invest Nova Scotia
Phase II funding: “Investigating a novel ALDH1A3 inhibitor for the treatment of cancer”
2024 - 2029
Canadian Institutes of Health Research (CIHR)
Targeting ALDH1A3 and investigating mechanisms of ALDH1A3-mediated breast cancer progression

InvestorsOur Valued Partners in Innovation

Get In TouchConnect with Us Today

Have questions about our groundbreaking cancer therapies or partnership opportunities? Reach out to Theranib Inc. and join us in advancing cancer care worldwide.

Get in Touch

Please enable JavaScript in your browser to complete this form.